AKTX
insider transactionsAkari Therapeutics Plc — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+11.1K
11.1K buy · 0 sell
Net value · 365d
$2.2K
$2.2K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
4
11.1K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$1.2K
3.1K sh · $0.40
Own New
-
Buy·P
Director
—
3.1K sh
Own New
-
Buy·P
Director
$999
2.5K sh · $0.40
Own New
-
Buy·P
Director
—
2.5K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 16, 2025 | James R Neal | Buy P | 3.1K | $1.2K |
| Dec 16, 2025 | James R Neal | Buy P | 3.1K | — |
| Dec 16, 2025 | James R Neal | Buy P | 2.5K | $999 |
| Dec 16, 2025 | James R Neal | Buy P | 2.5K | — |
About AKTX insider trading
This page tracks insider transactions for Akari Therapeutics Plc (AKTX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.